New pill targets Hard-to-Treat cancers in early human trial
NCT ID NCT07542704
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase study tests an experimental oral drug called KQB368 in 48 adults with advanced solid tumors (like lung, colorectal, or uterine cancer) that have a specific KRAS mutation (G12C or G12S). The main goals are to find a safe dose and see if the drug can shrink tumors. Participants take the drug daily in 21-day cycles and visit the clinic regularly for monitoring.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
KQB368 (oral drug)
What this could lead to
If it works, this could point toward a new treatment option for people with certain KRAS-mutated cancers that have stopped responding to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 48 participants, so it is primarily testing safety and dosing. It is too soon to know if KQB368 will shrink tumors or help patients feel better.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••